Tuesday, June 25, 2019

ANI Pharma launches Ranitidine Capsules

ANI Pharmaceuticals (NASDAQ:ANIP) has launched Ranitidine Capsules, 150mg and 300mg.
The annual U.S. market for this product is ~$40M, according to IQVIA Health.
Ranitidine Hydrochloride is an oral histamine H2-receptor antagonist with multiple indications.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.